title: Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
authors.forename: A L
authors.initials: AL
authors.lastname: Fauchais
authors.forename: S
authors.initials: S
authors.lastname: Prey
authors.forename: B
authors.initials: B
authors.lastname: Ouatara
authors.forename: E
authors.initials: E
authors.lastname: Vidal
authors.forename: A
authors.initials: A
authors.lastname: Sparsa
mesh_terms: D000328:Adult; D000794:Angiokeratoma / Q000188:drug therapy*; D056947:Enzyme Replacement Therapy / Q000379:methods*; D000795:Fabry Disease / Q000188:drug therapy*; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use*; D008297:Male; D012074:Remission Induction; D012611:Scrotum; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000627:therapeutic use*
chemical_list: D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta